Cerity Partners LLC Purchases New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Cerity Partners LLC purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 242,900 shares of the company's stock, valued at approximately $3,209,000. Cerity Partners LLC owned about 0.15% of Neumora Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics in the first quarter valued at approximately $10,354,000. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock valued at $9,224,000 after acquiring an additional 406,891 shares during the period. Callan Capital LLC boosted its stake in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company's stock worth $6,500,000 after acquiring an additional 456,207 shares in the last quarter. Auour Investments LLC acquired a new stake in Neumora Therapeutics in the third quarter worth $3,302,000. Finally, Bank of New York Mellon Corp increased its stake in Neumora Therapeutics by 474.1% in the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock valued at $2,316,000 after purchasing an additional 194,559 shares in the last quarter. Institutional investors and hedge funds own 47.65% of the company's stock.

Neumora Therapeutics Stock Performance

NASDAQ NMRA traded up $0.18 on Friday, hitting $9.94. The stock had a trading volume of 450,994 shares, compared to its average volume of 1,040,100. The firm has a 50-day moving average of $12.67 and a 200-day moving average of $11.48. Neumora Therapeutics, Inc. has a 52-week low of $8.33 and a 52-week high of $21.00. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.32 and a beta of 3.92.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the firm posted ($1.14) earnings per share. As a group, research analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Robert A. Lenz sold 30,788 shares of the firm's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares in the company, valued at $4,006,011.05. This trade represents a 8.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,400 shares of company stock worth $686,361 over the last three months. 26.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on NMRA. Needham & Company LLC restated a "buy" rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $29.00 price target on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $21.67.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.